Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The authors conducted a systematic review and meta-analysis of the available data on its efficacy against depression and suicidality as well as its side effects. METHODS: MEDLINE was searched with the keyword "esketamine" on March 24, 2024, using the PRISMA method. Data processing and statistical analysis were performed with R, version 4.3.3, and the meta-analysis was performed with the METAFOR package. RESULTS: Of 1,115 articles initially identified, 87 were included for analysis and discussion. At weeks 2-4, randomized controlled trials were mostly negative or failed; however, the meta-analysis returned a weak but significant positive effect for depression (effect size range, 0.15-0.23 at weeks 2-4), similar to augmentation strategies with atypical antipsychotics for treatment-resistant depression. The effect size concerning suicidality was not significant at any time point. The sensitivity analysis produced the same results. CONCLUSIONS: The study findings suggest that esketamine's efficacy as an add-on to antidepressants is modest in treatment-resistant depression (similar to augmentation strategies with atypical antipsychotics) and is absent against suicidality itself. These findings need to be considered in light of esketamine's abuse potential and the fact that long-term effects are still not fully known. Some alarming signs concerning deaths and emerging suicidality during the testing phase are discussed, along with other regulatory issues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Utilization of the PICO framework to improve searching PubMed for clinical questions
Schardt, C., Adams, M. B., Owens, T., Keitz, S., & Fontelo, P. (2007) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-7-16 · Cited by 3,053
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
Management of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Fu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m13191 · Cited by 376
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271
The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments
Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I. D., Salvadore, G., & Zarate, C. A. (2010) · Pharmaceuticals · doi:10.3390/ph3010019 · Cited by 263
Treatment-resistant depression and suicidality
Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.016 · Cited by 256
Marcantoni, W. S., Akoumba, B. S., Wassef, M., Mayrand, J., Lai, H., Richard-Devantoy, S., & Beauchamp, S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.007 · Cited by 246
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304145 · Cited by 222
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.010 · Cited by 219
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Witt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419883341 · Cited by 202
Correia-Melo, F. S., Leal, G. C., Vieira, F., Jesus-Nunes, A. P., Mello, R. P., Magnavita, G., Caliman-Fontes, A. T., Echegaray, M. V. F., Bandeira, I. D., Silva, S. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.086 · Cited by 193
Maintenance or Discontinuation of Antidepressants in Primary Care
Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106356 · Cited by 192
Kryst, J., Kawalec, P., Mitoraj, A. M., Pilc, A., Lasoń, W., & Brzostek, T. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00097-z · Cited by 159
Should protracted withdrawal from drugs be included in DSM-IV?
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.5.695 · Cited by 158
Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval
Turner, E. H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30394-3 · Cited by 156
Batelaan, N. M., Bosman, R. C., Muntingh, A., Scholten, W. D., Huijbregts, K. M., & van Balkom, A. J. L. M. (2017) · BMJ · doi:10.1136/bmj.j3927 · Cited by 153
Zaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D.-J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01577-5 · Cited by 137
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510703 · Cited by 134
Xiong, J., Lipsitz, O., Chen-Li, D., Rosenblat, J. D., Rodrigues, N. B., Carvalho, I., Lui, L. M. W., Gill, H., Narsi, F., Mansur, R. B., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.038 · Cited by 124
Illness risk following rapid versus gradual discontinuation of antidepressants
Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09060880 · Cited by 123
A Word to the Wise About Ketamine
Schatzberg, A. F. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101434 · Cited by 109
Self-citationEfficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis
Papakostas, G. I., Salloum, N. C., Hock, R. S., Jha, M. K., Murrough, J. W., Mathew, S. J., Iosifescu, D. V., & Fava, M. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19r12889 · Cited by 108
Standardisation framework for the Maudsley staging method for treatment resistance in depression
Fekadu, A., Donocik, J. G., & Cleare, A. J. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1679-x · Cited by 106
Turkoz, I., Alphs, L., Singh, J., Jamieson, C., Daly, E., Shawi, M., Sheehan, J. J., Trivedi, M. H., & Rush, A. J. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13260 · Cited by 104
Zheng, W., Cai, D.-B., Xiang, Y.-Q., Zheng, W., Jiang, W.-L., Sim, K., Ungvari, G. S., Huang, X., Huang, X.-X., Ning, Y.-P., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.002 · Cited by 99
Sartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B., Brand, U., Fleischhacker, W., Goodwin, G., Grunze, H., Knapp, M., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 98
Self-citationUS Food and Drug Administration approval of esketamine and brexanolone
Cristea, I. A., & Naudet, F. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30292-5 · Cited by 98
A Word to the Wise About Intranasal Esketamine
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19040423 · Cited by 96
Self-citationVázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013579 · Cited by 95
Predicting relapse after antidepressant withdrawal – a systematic review
Berwian, I. M., Walter, H., Seifritz, E., & Huys, Q. J. M. (2017) · Psychological Medicine · doi:10.1017/s0033291716002580 · Cited by 93
Trapped in the "K-hole": Overview of Deaths Associated With Ketamine Misuse in the UK (1993-2006)
Schifano, F., Corkery, J., Oyefeso, A., Tonia, T., & Ghodse, A. H. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181612cdc · Cited by 89
Thomases, D. R., Cass, D. K., & Tseng, K. Y. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4147-12.2013 · Cited by 89
Canuso, C. M., Ionescu, D. F., Li, X., Qiu, X., Lane, R., Turkoz, I., Nash, A. I., Lopena, T. J., & Fu, D.-J. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001465 · Cited by 88
Scott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221104058 · Cited by 87
Esketamine: A Novel Option for Treatment-Resistant Depression
Bozymski, K. M., Crouse, E. L., Titus-Lay, E. N., Ott, C. A., Nofziger, J. L., & Kirkwood, C. K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028019892644 · Cited by 82
Hudgens, S., Floden, L., Blackowicz, M., Jamieson, C., Popova, V., Fedgchin, M., Drevets, W. C., Cooper, K., Lane, R., & Singh, J. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.066 · Cited by 80
Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder
Kryst, J., Kawalec, P., & Pilc, A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1683161 · Cited by 77
Fountoulakis, K. N., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Tohen, M., Kasper, S., & Moeller, H. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz064 · Cited by 77
Self-citationBschor, T., & Baethge, C. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01458.x · Cited by 75
A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect
Lee, Y., Syeda, K., Maruschak, N. A., Cha, D. S., Mansur, R. B., Wium-Andersen, I. K., Woldeyohannes, H. O., Rosenblat, J. D., & McIntyre, R. S. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000441 · Cited by 74
Esketamine: a glimmer of hope in treatment-resistant depression
Kaur, U., Pathak, B. K., Singh, A., & Chakrabarti, S. S. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01084-z · Cited by 74
Bahji, A., Zarate, C. A., & Vazquez, G. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047928 · Cited by 73
(2022) · doi:10.1192/bja.2021.62 · Cited by 73
Hengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72
Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
Salahudeen, M. S., Wright, C. M., & Peterson, G. M. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620937899 · Cited by 72
Chen, G., Chen, L., Zhang, Y., Li, X., Lane, R., Lim, P., Daly, E. J., Furey, M. L., Fedgchin, M., Popova, V., et al. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab084 · Cited by 71
Siegel, A. N., Di Vincenzo, J. D., Brietzke, E., Gill, H., Rodrigues, N. B., Lui, L. M. W., Teopiz, K. M., Ng, J., Ho, R., McIntyre, R. S., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.009 · Cited by 70
Caldiroli, A., Capuzzi, E., Tagliabue, I., Capellazzi, M., Marcatili, M., Mucci, F., Colmegna, F., Clerici, M., Buoli, M., & Dakanalis, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313070 · Cited by 70
Henssler, J., Bschor, T., & Baethge, C. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743715620411 · Cited by 64
Cheng, J. Y. K., Chan, D. T. W., & Mok, V. K.-K. (2004) · Forensic Science International · doi:10.1016/j.forsciint.2004.08.023 · Cited by 57
Takahashi, N., Yamada, A., Shiraishi, A., Shimizu, H., Goto, R., & Tominaga, Y. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03538-y · Cited by 57
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
Jollant, F., Colle, R., Nguyen, T. M. L., Corruble, E., Gardier, A. M., Walter, M., Abbar, M., & Wagner, G. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231151327 · Cited by 56
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 54
Self-citationEsketamine for treatment resistant depression: a trick of smoke and mirrors?
Gastaldon, C., Papola, D., Ostuzzi, G., & Barbui, C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000751 · Cited by 54
Psiuk, D., Nowak, E., Dycha, N., Łopuszańska, U., Kurzepa, J., & Samardakiewicz, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911450 · Cited by 54
Are we repeating mistakes of the past? A review of the evidence for esketamine
Horowitz, M. A., & Moncrieff, J. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2020.89 · Cited by 53
Levinstein, M. R., Carlton, M. L., Di Ianni, T., Ventriglia, E. N., Rizzo, A., Gomez, J. L., Budinich, R. C., Shaham, Y., Airan, R. D., Zarate, C. A., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.12.019 · Cited by 53
Wang, S.-M., Kim, N.-Y., Na, H.-R., Lim, H. K., Woo, Y. S., Pae, C.-U., & Bahk, W.-M. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.2.341 · Cited by 52
Ng, J., Rosenblat, J. D., Lui, L. M. W., Teopiz, K. M., Lee, Y. L., Lipsitz, O., Mansur, R. B., Rodrigues, N. B., Nasri, F., Gill, H., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.06.032 · Cited by 50
Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses
Lima, T. D. M., Visacri, M. B., & Aguiar, P. M. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03216-8 · Cited by 50
Daly, E. J., Turkoz, I., Salvadore, G., Fedgchin, M., Ionescu, D. F., Starr, H. L., Borentain, S., Trivedi, M. H., Thase, M. E., & Singh, J. B. (2021) · Depression and Anxiety · doi:10.1002/da.23193 · Cited by 46
Rodolico, A., Cutrufelli, P., Francesco, A. D., Aguglia, A., Catania, G., Concerto, C., Cuomo, A., Fagiolini, A. M., Lanza, G., Mineo, L., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1325399 · Cited by 45
Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
Katz, E. G., Hough, D. W., Doherty, T., Lane, R., Singh, J. B., & Levitan, B. S. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2024 · Cited by 43
Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine
Mathai, D. S., Nayak, S. M., Yaden, D. B., & Garcia‐Romeu, A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06324-8 · Cited by 43
Capuzzi, E., Caldiroli, A., Capellazzi, M., Tagliabue, I., Marcatili, M., Colmegna, F., Clerici, M., Buoli, M., & Dakanalis, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179338 · Cited by 41
Jesus‐Nunes, A. P., Leal, G. C.-G., Correia‐Melo, F. S., Vieira, F., Mello, R. P., Caliman‐Fontes, A. T., Echegaray, M. V. F., Marback, R. F., Guerreiro‐Costa, L. N. F., Souza‐Marques, B., et al. (2022) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2836 · Cited by 39
Chen, C., Zhou, N., Hu, N., Feng, J., & Wang, X. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s401032 · Cited by 39
Jawad, M. Y., Vincenzo, J. D. D., Ceban, F., Jaberi, S., Lui, L. M. W., Gillissie, E. S., Alnefeesi, Y., Rosenblat, J. D., & McIntyre, R. S. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2058488 · Cited by 37
Chen, X., Hou, X., Bai, D., Lane, R., Zhang, C., Canuso, C., Wang, G., & Fu, D.-J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s391096 · Cited by 35
Dold, M., Bartova, L., & Kasper, S. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa034 · Cited by 34
Vieira, F., Correia‐Melo, F. S., Santos‐Lima, C., Souza‐Marques, B., Leal, G. C.-G., Jesus‐Nunes, A. P., Mello, R. P., Caliman‐Fontes, A. T., Bandeira, I. D., Marback, R. F., et al. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2020.12.011 · Cited by 34
Jones, R., Freeman, M. P., Kornstein, S. G., Cooper, K., Daly, E., Canuso, C. M., & Nicholson, S. (2022) · Archives of Women s Mental Health · doi:10.1007/s00737-021-01185-6 · Cited by 34
Boudieu, L., Mennetrier, M., Llorca, P., & Samalin, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122773 · Cited by 32
Wang, Y., Wang, X., Lan, L., Guo, Z., Kan, F., Hu, D., Gai, C., & Zhang, Y. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03605-1 · Cited by 32
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. N., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0274-7 · Cited by 30
Self-citationFountoulakis, K. N., & Möller, H.-J. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111421969 · Cited by 30
Self-citationJamieson, C., Popova, V., Daly, E., Cooper, K., Drevets, W. C., Rozjabek, H., & Singh, J. B. (2023) · Health and Quality of Life Outcomes · doi:10.1186/s12955-023-02113-1 · Cited by 30
Borentain, S., Williamson, D., Turkoz, I., Popova, V., McCall, W. V., Mathews, M., & Wiegand, F. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s339090 · Cited by 29
The antidepressant effect and safety of non-intranasal esketamine: A systematic review
Smith-Apeldoorn, S. Y., Vischjager, M., Veraart, J. K. E., Kamphuis, J., Rot, M. A. H., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221084055 · Cited by 29
Citrome, L., DiBernardo, A., & Singh, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.106 · Cited by 26
Lengvenytė, A., Olié, É., Strumila, R., Navickas, A., González-Pinto, A. M., & Courtet, P. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1907712 · Cited by 26
Nikayin, S., & Sanacora, G. (2021) · CNS Drugs · doi:10.1007/s40263-021-00851-8 · Cited by 26
Wong, S., Kwan, A. T. H., Teopiz, K. M., Le, G. H., Meshkat, S., Ho, R., d’Andrea, G., Cao, B., Vincenzo, J. D. D., Rosenblat, J. D., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.142 · Cited by 26
Pérez, M. Á., Morales, C., Santander, O., García, F., Gómez, I., Peñaloza‐Sancho, V., Fuentealba, P., Dagnino‐Subiabre, A., Moya, P. R., & Fuenzalida, M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00372 · Cited by 25
Turkoz, I., Daly, E., Singh, J. B., Lin, X., Tymofyeyev, Y., Williamson, D., Salvadore, G., Nash, A. I., Macaluso, M., Wilkinson, S. T., et al. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13800 · Cited by 25
Turkoz, I., Nelson, J. C., Wilkinson, S. T., Borentain, S., Macaluso, M., Trivedi, M. H., Williamson, D., Sheehan, J. J., Salvadore, G., Singh, J. B., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115165 · Cited by 25
Targum, S. D., Daly, E., Fedgchin, M., Cooper, K., & Singh, J. B. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.017 · Cited by 24
Agboola, F., Atlas, S. J., Touchette, D. R., Fazioli, K., & Pearson, S. D. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.1.16 · Cited by 24
Morrens, J., Mathews, M., Popova, V., Borentain, S., Rive, B., Gonzalez Martin Moro, B., Jamieson, C., & Zhang, Q. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s358367 · Cited by 24
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
Fu, D., Zhang, Q., Shi, L., Borentain, S., Guo, S., Mathews, M., Anjo, J., Nash, A. I., O’Hara, M., & Canuso, C. M. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05017-y · Cited by 24
Hengartner, M. P., & Plöderl, M. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032051 · Cited by 23
Jha, M. K., Williamson, D., Magharehabed, G., Turkoz, I., Daly, E., & Trivedi, M. H. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.10.020 · Cited by 23
Floden, L. L., Hudgens, S. A., Jamieson, C., Popova, V., Drevets, W. C., Cooper, K., & Singh, J. B. (2022) · CNS Drugs · doi:10.1007/s40263-022-00916-2 · Cited by 22
Intranasal esketamine: A novel drug for treatment-resistant depression
Khorassani, F., & Talreja, O. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa191 · Cited by 21
Mello, R. P., Echegaray, M. V. F., Jesus-Nunes, A. P., Leal, G. C., Magnavita, G. M., Vieira, F., Caliman-Fontes, A. T., Telles, M., Guerreiro-Costa, L. N. F., Souza-Marques, B., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.014 · Cited by 21
Liu, P., Zhang, S., Liang, Y., Gao, Z., Gao, W., & Dong, B. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s388764 · Cited by 21
Diekamp, B., Borentain, S., Fu, D., Murray, R., Heerlein, K., Zhang, Q., Schüle, C., & Mathews, M. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s314874 · Cited by 18
Jamieson, C., Canuso, C. M., Ionescu, D. F., Lane, R., Qiu, X., Rozjabek, H., Molero, P., & Fu, D. (2023) · Quality of Life Research · doi:10.1007/s11136-023-03451-9 · Cited by 18
Burning issues in the meta-analysis of pharmaceutical trials for depression
Fountoulakis, K. Ν., Samara, M. T., & Siamouli, M. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113504014 · Cited by 17
Self-citationAbrupt Withdrawal of Antidepressant Treatment
Freedman, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10050783 · Cited by 17
Tsapakis, E.-M., Preti, A., Mintzas, M. D., & Fountoulakis, K. Ν. (2020) · CNS Spectrums · doi:10.1017/s109285292000156x · Cited by 16
Self-citationN. Fountoulakis, K., S. McIntyre, R., & F. Carvalho, A. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630174343 · Cited by 15
Self-citationZhou, D., Lv, Z., Shi, L., Zhou, X., Lin, Q., Chen, X., Wan, L.-Y., Li, Y., Ran, L., Huang, Y., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720001610 · Cited by 14
Xiao, C., Zhou, J. L., Li, A., Zhang, L., Zhu, X., Zhou, J., Hu, Y., Zheng, Y., Liu, J., Deng, Q., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.28817 · Cited by 14
Comment on a Word to the Wise About Intranasal Esketamine
Drevets, W. C., Singh, J. B., Hough, D., Daly, E. J., Popova, V., & Manji, H. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19070688 · Cited by 12
Diversity inclusion in clinical trials investigating esketamine for depression: A systematic review.
Monahan, K., Weyandt, L. L., & Shepard, E. (2022) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000601 · Cited by 12
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder
Hock, R. S., Feeney, A., Iovieno, N., Murrough, J. W., Mathew, S. J., Iosifescu, D. V., D, M. F. M., Jha, M. K., & Papakostas, G. I. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21r14086 · Cited by 12
Floriano, I., Silvinato, A., & Bernardo, W. M. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.2023d694 · Cited by 12
Esketamine: uncertain safety and efficacy data in depression
Horowitz, M. A., & Moncrieff, J. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.163 · Cited by 11
Rozjabek, H., Li, N., Hartmann, H., Fu, D., Canuso, C. M., & Jamieson, C. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00453-y · Cited by 11
The why, when, where, how, and so what of so-called rapidly acting antidepressants
Schatzberg, A. F., & Mathew, S. J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01647-8 · Cited by 11
Self-citationFountoulakis, K. Ν., Karavelas, V., Moysidou, S., Mavridis, D., Pastiadis, K., Petalidou, N., Nimatoudis, I., & Kasper, S. F. (2018) · Pharmacopsychiatry · doi:10.1055/a-0695-9223 · Cited by 10
Self-citationFloriano, I., Silvinato, A., & Bernardo, W. M. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.2023d696 · Cited by 9
Ohnishi, T., Wakamatsu, A., & Kobayashi, H. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13379 · Cited by 7
Hong, J. P., Malek, A. Z. A., Li, C., Paik, J., Sulaiman, A. H., Madriaga, G. O., Zhuo, J., Siggins, S., Fu, D., & Ju, P. (2023) · Asia-Pacific Psychiatry · doi:10.1111/appy.12548 · Cited by 5
Fountoulakis, K. Ν., & Tsapakis, E.-M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02458-z · Cited by 5
Self-citationFountoulakis, K. Ν. (2017) · Evidence-Based Mental Health · doi:10.1136/eb-2016-102606 · Cited by 1
Self-citationThe cognitive effects of esketamine: what do we know so far?
Barbosa, M., & Guedes, R. D. A. S. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.1879 · Cited by 1
Research works printed but not linked: 5
- Kohrs R, 1998, Anesth Analg, 87, 1186
- Huang X, 2006, AMIA Annu Symp Proc, 2006, 359
- Turkoz I, 2022, CNS Spectr, 28, 1
- Echegaray MVF, Trends Psychiatry Psychother
- Sapkota A, 2021, Cureus, 13, e17352
Cited by
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Malhi, G. S., Bell, E., Stavdal, A., Wu, C., Naylor, A., & Kumari, V. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00201-1 · Cited by 22
Recommendations for defining treatment outcomes in major psychiatric disorders using real-world data
Koch, E. M., Smart, S. E., Einarsson, G., Kämpe, A. J., Jönsson, L., Alver, M., Iveson, M. H., Göteson, A., Pardiñas, A. F., Sønderby, I. E., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00061-6 · Cited by 17
Pharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
“In this review, four systematic review and meta-analyses of intranasal esketamine [46–49], and six phase III trials [50–56] were included.”
Lapa, C. D. O., Viola, T. W., Delfino, R. S., Dutra, L., Rubira, G., Rodrigues, R. J. K., Castro, S. C. C., Ramos‐Quiroga, J. A., & Spanemberg, L. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121257 · Cited by 15
Metadata
- Authors
- Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F.
- Affiliations
- 3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece (Fountoulakis, Saitis); Stanford University Mood Disorders Center and Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford (Schatzberg).
- Aristotle University of Thessaloniki (GR)
- Venue
- American Journal of Psychiatry
- Published
- 2025-03-01
- Volume
- 182
- Issue
- 3
- Pages
- 259-275
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4406934817
- Semantic Scholar
- 9c239b8a3b0ae8395b77aceca18671b97025faf8
- Cited by
- 90
- References
- 133
- Citations by year
- 2026: 51 · 2025: 38
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, treatment-resistant depression, major depressive disorder, suicidal ideation, adjunctive therapy, atypical antipsychotics, antidepressant augmentation, adverse drug reactions, abuse liability
- MeSH terms
- Administration, Intranasal, Adult, Antidepressive Agents, Major Depressive Disorder, Humans, Ketamine, Randomized Controlled Trials as Topic, Suicidal Ideation, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.